Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Tech Journal.
Press releases published on August 13, 2025
Aterian Reports 2025 Second Quarter Financial Results and Provides Guidance for the Second Half of 2025
GlobeNewswire
·
August 13, 2025
SUMMIT, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products company, today announced financial results for the second quarter ended June 30, 2025 (“Q2 2025”) and provided net revenue and …
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
GlobeNewswire
·
August 13, 2025
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 STRENGTH trial to …
Odysight.ai Reports Financial Results for The First Half of 2025 and Provides Business Update
GlobeNewswire
·
August 13, 2025
OMER, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, announces its financial results for the first half of 2025 and …
Wallchain Launches Free Mindshare Leaderboard for All CT accounts
GlobeNewswire
·
August 13, 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- – Wallchain, one of the leading AttentionFI and InfoFi projects, is announcing the launch of free leaderboards for every person on crypto Twitter/X. Some crypto projects spend millions and wait months to launch …
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 13, 2025
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell …
dLocal announces appointment of Chief Financial Officer
GlobeNewswire
·
August 13, 2025
MONTEVIDEO, Uruguay, Aug. 13, 2025 (GLOBE NEWSWIRE) -- DLocal Limited (“dLocal”, “we”, “us”, and “our”) (NASDAQ:DLO), a technology - first payments platform, today announced the appointment of Guillermo López Pérez as Chief Financial Officer, who will join …
dLocal Reports 2025 Second Quarter Financial Results
GlobeNewswire
·
August 13, 2025
TPV at record high of US$9.2 billion, growing more than 50% YoY for the third consecutive quarter. Brazil and Mexico posted solid results, while growth remains fastest in the rest of our geographies, leading to increased diversification. Consistent …
AirJoule Technologies Announces Second Quarter 2025 Results
GlobeNewswire
·
August 13, 2025
RONAN, Mont., Aug. 13, 2025 (GLOBE NEWSWIRE) -- AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or the “Company”), a leading technology platform that unleashes the power of water from air, today announced its second quarter 2025 …
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 13, 2025
Reported positive topline data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Enrolled approximately 5,000 participants in COVID-19 …
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 13, 2025
Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication ELPIS II top-line trial results are anticipated in the …
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 13, 2025
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of JADE101 expected to begin in the …
Codexis Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 13, 2025
Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to …
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
August 13, 2025
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard Fludarabine and Cyclophosphamide (FC …
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 13, 2025
- Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% overall survival (OS) observed at 6 months in ongoing …
Roadzen Reports Best Fiscal Q1 in Company History with 22% Revenue Growth, 92% Lower Net Loss, and 50% Adjusted EBITDA Improvement Over the Same Quarter Last Year
GlobeNewswire
·
August 13, 2025
1. Record Fiscal Q1 Revenue Sets Stage for the Year Ahead First quarter fiscal 2026 revenue increased 22% to $10.9 million from $8.9 million last year – the strongest first quarter revenue on record for Roadzen, driven by growth in India and the U.S., …
HeartCore Reports Financial Results for Second Quarter and Six Months Ended June 30, 2025
GlobeNewswire
·
August 13, 2025
NEW YORK and TOKYO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the second quarter …
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
GlobeNewswire
·
August 13, 2025
CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster …
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 13, 2025
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE …
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
GlobeNewswire
·
August 13, 2025
KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial …
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 13, 2025
–Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b LUMUS clinical trial for envudeucitinib in systemic lupus …